Improved In-Vitro Fertilisation (IVF) implantation success rate using advanced proteomic analysis of embryo culture fluid.

利用胚胎培养液的先进蛋白质组学分析提高体外受精 (IVF) 植入的成功率。

• 批准号: 10034129
• 金额: $ 25.09万
• 依托单位: MAP IP HOLDING LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10034129
• 关键词: Improved; Vitro; Fertilisation; IVF; implantation

Infertility affects one in seven couples in the UK. Endometriosis, polycystic ovaries, or ovulation disorders affect 20% of women, while male infertility is rising significantly. The WHO recognises infertility as a disease, and the devastation and grief it causes is widely acknowledged.The NHS provides limited IVF support for infertile couples but is cutting provision. Private clinics service the need but with multiple cycles usually required and a 25-30% success rate, the costs (£1,500 - £5,000 per cycle) and stress involved are extremely high.Embryos vary in quality, the best most likely to implant and lead to a pregnancy. Embryologists use training and expertise to select embryos using physical criteria and observation but the process is time consuming and subjective. Embryoscope and AI technology potentially improves the outcome but is limited to 12 embryos per 3-5 day session and provides only visual information.There is a strong market need for a non-invasive, predictive technology, with high throughput and low cost, that can improve implantation success rate, and reduce the number of cycles.MAP Sciences has developed a diagnostic platform using Matrix Assisted Laser Desorption Ionisation Time of Flight Mass Spectrometry (MALDI-ToF) and advanced protein pattern recognition, using Artificial Intelligence, to diagnose disease states from clinical samples.MAP's research indicates strong correlation for rapid profiling of embryo culture media to select those embryos with highest implantation potential. MAP's ground-breaking technology provides high quality, objective metabolic data for optimal decision making, to radically improve implantation success rate. Key features of the technology are that is not invasive or tissue destructive, is rapid, high throughput, and affordable. Patents are granted in UK. France, Germany, China.Map requires resources to expand data sets and scope by collaborating with IVF clinics to collect samples and data to validate the technology both technically and commercially and create a final product with IVDR -- FDA validation.MAP has secured commitment from instrument manufacturers to ensure rapid introduction and robust support of MAP's software/reagent technology alongside existing and newly introduced machines.A successful project outcome is important clinically, commercially, and from the patient's perspective, emotionally and financially.

在英国，每七对夫妇中就有一对患有不孕症。子宫内膜异位症、多囊卵巢或排卵障碍影响20%的女性，而男性不孕症显著增加。世界卫生组织承认不孕不育是一种疾病，它造成的破坏和悲伤也是广为人知的。NHS为不育夫妇提供的试管受精支持有限，但正在削减供应。私人诊所可以满足这一需求，但由于通常需要多个周期，成功率为25%-30%，成本(每个周期1,500-5,000 GB)和压力极高。胚胎质量参差不齐，最有可能植入并导致怀孕。胚胎学家利用训练和专业知识，使用物理标准和观察来选择胚胎，但这个过程既耗时又主观。胚胎镜和人工智能技术可能会改善结果，但仅限于每3-5天12个胚胎，且仅提供视觉信息。市场对非侵入性、预测性技术的强烈需求，具有高通量和低成本，可以提高植入成功率，并减少周期数。MAP Sciences开发了一个诊断平台，使用基质辅助激光解吸电离飞行时间质谱仪(MALDI-ToF)和先进的蛋白质模式识别，使用人工智能来诊断临床样本的疾病状态。MAP的研究表明，快速分析胚胎培养液以选择最具植入潜力的胚胎具有很强的相关性。MAP的突破性技术为优化决策提供高质量、客观的代谢数据，从根本上提高植入成功率。该技术的主要特点是非侵入性或组织破坏性、快速、高通量和经济实惠。专利是在英国授予的。法国、德国、中国。MAP需要资源来扩大数据集和范围，通过与试管受精诊所合作收集样本和数据，以在技术和商业上验证该技术，并通过IVDR-FDA验证创建最终产品。MAP已获得仪器制造商的承诺，确保快速引入MAP的软件/试剂技术，并在现有和新引入的机器的基础上提供强有力的支持。成功的项目结果在临床、商业、从患者的角度、情感和经济上都很重要。